Berkowitz J M
J Clin Psychiatry. 1978 Oct;39(10 Pt 2):46-52.
The effectiveness of lorazepam was assessed under double-blind conditions in 70 ambulant patients suffering from anxiety associated with gastrointestinal symptomatology. In this 4-week study, the usual daily dose of lorazepam, 3.0 mg given in a b.i.d. regimen, produced a greater decrease in symptoms associated with anxiety than placebo at almost all evaluation periods, as indicated by Kruskal-Wallis analyses of Global, Hamilton, and 35-Item ratings--a decrease which was clinically and statistically significant. In addition, lorazepam was well accepted and well tolerated by the majority of patients and was compatible with concomitant medications. Side effects were infrequent and usually controlled by dosage adjustment.
在双盲条件下，对70名患有与胃肠道症状相关焦虑症的门诊患者评估了劳拉西泮的疗效。在这项为期4周的研究中，按照每日两次的服药方案给予的常规日剂量3.0毫克劳拉西泮，在几乎所有评估期内，与安慰剂相比，在与焦虑相关的症状方面产生了更大程度的减轻，这由对整体、汉密尔顿和35项评分的克鲁斯卡尔-沃利斯分析表明——这种减轻在临床和统计学上均具有显著意义。此外，大多数患者对劳拉西泮接受度良好且耐受性良好，并且与同时服用的药物相容。副作用很少见，通常通过调整剂量来控制。
